Key Takeaways
- Pico IV's CBD IV therapy is now available in over 200 clinics across nearly all 50 states, reflecting rapid growth since its launch.
- The therapy utilizes a patent-pending process to reduce CBD particles to picometer size, ensuring safe intravenous use.
- Users report significant benefits, including improved management of conditions like Crohn’s disease.
- Pico IV has also introduced a broad-spectrum CBD formula, including additional cannabinoids for enhanced therapeutic effects.
Pico IV has significantly expanded the availability of its CBD IV therapy, now offered in over 200 clinics across almost all 50 states, just a year after its debut.
According to a news release, the company has shipped over 15,000 doses of CBD, meeting a strong market demand for intravenous cannabinoid treatments.
The product was previously highlighted in Forbes for its breakthrough in IV therapy.
ALSO READ: Legacy Cup IV Marks Minnesota’s Largest Cannabis Gathering Post-Legalization
The news release detailed that the initial challenge in developing intravenous CBD products stemmed from the particle size, which was too large for sterile filtration.
However, with advancements in nanotechnology, the company developed a patent-pending process to reduce cannabinoid particles to picometer size, making them small enough to pass through a 0.1-micron sterile filter.
This advancement allows for safe and effective intravenous use, with rigorous third-party testing ensuring product purity and potency.
Joe Young, CEO of Pico IV, expressed astonishment at the positive reception of their CBD IV infusions, noting the transformative impact on users.
He emphasized the company's pride in leading this innovation within the IV therapy industry.
ALSO READ: Germany’s Green Wave: Cannabis Legalization and European Stance
The news release also highlighted the development of Pico IV's broad-spectrum CBD, which includes additional cannabinoids such as CBG, CBN, CBD-a, and CBC.
This formulation aims to enhance the therapeutic effects through an entourage effect, where the combined cannabinoids work more effectively.
Pico IV's commitment to safety and innovation is further demonstrated by its recent membership in the American IV Association (AIVA), which promotes best practices and safety in IV hydration therapy.
More details in this news release.